Minzasolmin

Minzasolmin
Names
	IUPAC name N-[(2R)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
Identifiers
CAS Number	1802518-92-8;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL5095072;
ChemSpider	115010423;
KEGG	D12796;
PubChem CID	118279413;
UNII	3N0435TG2D;
	InChI InChI=1S/C23H31N5OS/c1-3-4-7-18(14-17-15-24-20-9-6-5-8-19(17)20)26-22(29)21-16-25-23(30-21)28-12-10-27(2)11-13-28/h5-6,8-9,15-16,18,24H,3-4,7,10-14H2,1-2H3,(H,26,29)/t18-/m1/s1 Key: GDFWCSZNQVAQGR-GOSISDBHSA-N;
	SMILES CCCC[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C3=CN=C(S3)N4CCN(CC4)C;
Properties
Chemical formula	C23H31N5OS
Molar mass	425.60 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Minzasolmin (development names DLX313 and UCB0599) is an experimental small-molecule drug in development for Parkinson's disease that is designed to prevent misfolding of α-synuclein.